Triggered Escalating Real-Time Adherence Intervention to Promote Rapid HIV Viral Suppression Among Youth Living With HIV Failing Antiretroviral Therapy: Protocol for a Triggered Escalating Real-Time Adherence Intervention.

TitleTriggered Escalating Real-Time Adherence Intervention to Promote Rapid HIV Viral Suppression Among Youth Living With HIV Failing Antiretroviral Therapy: Protocol for a Triggered Escalating Real-Time Adherence Intervention.
Publication TypePublication
Year of Publication2019
AuthorsK Amico R, Dunlap A, Dallas R, Lindsey J, Heckman B, Flynn P, Lee S, Horvath K, Goolsby RWest, Hudgens M, Filipowicz T, Polier M, Hill E, Johnson MMueller, Miller J, Neilan A, Ciaranello A, Gaur A
JournalJMIR Res Protoc
Volume8
Issue3
Paginatione11416
Date Published2019 Mar 18
ISSN1929-0748
Abstract

<p><b>BACKGROUND: </b>Youth living with HIV (YLWH) are confronted with many self-care challenges that can be experienced as overwhelming in the context of normal developmental processes that characterize adolescence and young adulthood. A sizable minority of YLWH have unsuppressed viral loads in the United States attributable to antiretroviral therapy (ART) nonadherence. Interventions to promote sustained viral suppression in YLWH are needed.</p><p><b>OBJECTIVE: </b>The aim of this study is to evaluate the efficacy of the Triggered Escalating Real-Time Adherence (TERA) intervention in comparison with standard of care (SOC) in YLWH (aged 13-24 years) failing ART on (1) primary outcome measures-HIV viral suppression (VLS), defined as both <200 copies/ml and <50 copies/ml at 12 weeks, and (2) secondary outcome measures-VLS rates and rates of ART adherence at 24, 36, and 48 weeks as well as patterns of adherence over time as measured by an electronic dose monitoring (EDM) device.</p><p><b>METHODS: </b>The TERA study is a phase 2, multisite clinical trial conducted with 120 YLWH failing ART (randomized 1:1 to TERA or SOC) at participating clinical sites within the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN). Participants are followed for a total of 48 weeks. For TERA arm participants, the first 12 weeks involve delivery of the intervention. For all participants, clinical outcomes are collected throughout follow-up, and adherence is assessed using EDM over the full 48 weeks. During the 12-week intervention period, TERA arm participants receive 3 remote coaching sessions delivered in clinic via videoconferencing timed to coincide with baseline and follow-up clinical visits, text message reminders when the EDM has not been opened at dose time (which escalate to 2-way theory-informed short message service coaching interactions in response to real-time nonadherence), and review of dosing graphs produced by EDM at follow-up visits.</p><p><b>RESULTS: </b>Launch dates for enrollment varied by site. Enrollment began in April 2018 and is expected to be completed by August 2019, with results presented by the second quarter of 2021.</p><p><b>CONCLUSIONS: </b>Effective, generalizable, and scalable approaches to rapidly assist YLWH failing to achieve and sustain VLS may have a substantial impact on individual health and efforts to curb transmission. Coaching for a brief but intensive period from remote coaches and using communication channels common to youth may offer multiple unique advantages in promoting self-care.</p><p><b>TRIAL REGISTRATION: </b>ClinicalTrials.gov NCT03292432; https://clinicaltrials.gov/ct2/show/NCT03292432 (Archived by WebCite at http://www.webcitation.org/768J8ijjp).</p><p><b>INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): </b>DERR1-10.2196/11416.</p>

DOI10.2196/11416
Alternate JournalJMIR Res Protoc
PubMed ID30882360
PubMed Central IDPMC6441855
Grant ListP30 AI050410 / AI / NIAID NIH HHS / United States
U24 HD089880 / HD / NICHD NIH HHS / United States
UM1 AI069536 / AI / NIAID NIH HHS / United States